• レポートコード:MRC2303K094 • 出版社/出版日:Mordor Intelligence / 2023年2月 • レポート形態:英文、PDF、106ページ • 納品方法:Eメール(受注後2-3営業日) • 産業分類:医療 |
Single User | ¥712,500 (USD4,750) | ▷ お問い合わせ |
Corporate License | ¥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の調査レポートでは、世界のハンティントン病治療市場規模が、予測期間中、CAGR 21%で増大すると予測されています。本レポートでは、ハンティントン病治療の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別(対症療法、疾患修飾療法)分析、流通チャネル別(病院内薬局、小売薬局、オンライン薬局)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Pfizer, Inc.、Alnylam Pharmaceuticals Inc、Ceregene Inc.、Prana Biotechnology Limited、Teva Pharmaceutical Industries Ltd.、Ionis Pharmaceuticals、Neurocrine Biosciences, Inc.、Prilenia Therapeutics、Azevan Pharmaceuticals、Lundbeckなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のハンティントン病治療市場規模:種類別 - 対症療法の市場規模 - 疾患修飾療法の市場規模 ・世界のハンティントン病治療市場規模:流通チャネル別 - 病院内薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のハンティントン病治療市場規模:地域別 - 北米のハンティントン病治療市場規模 アメリカのハンティントン病治療市場規模 カナダのハンティントン病治療市場規模 メキシコのハンティントン病治療市場規模 … - ヨーロッパのハンティントン病治療市場規模 ドイツのハンティントン病治療市場規模 イギリスのハンティントン病治療市場規模 フランスのハンティントン病治療市場規模 … - アジア太平洋のハンティントン病治療市場規模 中国のハンティントン病治療市場規模 日本のハンティントン病治療市場規模 インドのハンティントン病治療市場規模 … - 南米/中東のハンティントン病治療市場規模 南アフリカのハンティントン病治療市場規模 ブラジルのハンティントン病治療市場規模 アルゼンチンのハンティントン病治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The Huntington’s disease treatment market is projected to register a CAGR of 21% during the forecast period.
The outbreak of COVID-19 has adversely affected the global economy as well as the healthcare system. The sudden imposition of lockdown policies and social distancing mandates by the government bodies not only disrupted the supply chains but also impeded the ongoing research programs related to Huntington’s disease. This has resulted in the slowdown of product R&D process and approval, thereby affecting market revenue growth. Nonetheless, operating key stakeholders including regulatory bodies, market players, research academics, and others are undertaking various market strategies to mitigate the negative impact of the COVID-19 pandemic on the market. For instance, several onsite trial visits are converted into telephone calls. Also, several research institutes began investigating COVID-19 impact on Huntington’s disease patients as well as to improve their care and management. For instance, a research article was published in the Journal Of Huntington’s Disease in April 2021 that discussed the healthcare delivery and safer-at-home orders during the COVID-19 pandemic for Huntington’s disease patients.
With the high penetration of symptomatic treatments, key players are engaged in capitalizing untapped avenues by the development of novel therapies that target pathways specific to Huntington’s disease biology to slow down disease progression. For instance, in April 2021, Voyager Therapeutics, Inc. received the United States Food and Drug Administration (FDA) clearance for IND application for its VY-HTT, a gene therapy candidate designed for the treatment of Huntington’s disease. The therapy is designed to reduce the expression of huntingtin gene to further alter the disease progression. Similarly, in December 2021, uniQure N.V. presented clinical outcomes for the first four patients enrolled in the lower-dose cohort of its ongoing Phase I/II clinical trial of AMT-130. AMT-130 is a gene therapy program designed for the treatment of Huntington’s disease.
Furthermore, an increase in the number of cases coupled with expanding geriatric population is driving the market revenue. As reported in Neuroepidemiology 2021 journal, the prevalence of this disease is around 10 cases per 100,000 people, with a higher prevalence in North America, North-western Europe, the Middle East, and Australia. In these regions, the estimates range from 5.96 to 13.70 cases per 100,000 people. Whereas in Asia, the prevalence is estimated to be 0.41–0.70 cases per 100,000 people.
Huntingtons Disease Treatment Market Trends
The Symptomatic Treatment Segment is Expected to Hold a Major Market Share in the Huntington’s Disease Treatment Market
The symptomatic treatment segment is expected to account for the major share during the forecast period. Relatively high availability and usage rate of symptom management therapeutics have bolstered the segment revenue. Need for multiple treatments and the intervention of a multispecialty care team for symptomatic management results in additional expense, thereby high revenue generation through this segment.
Symptomatic therapeutic development majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington’s disease for which most of the therapeutic studies have been carried out. For instance, in December 2021, Neurocrine Biosciences announced valbenazine has significantly lessened chorea in people with Huntington’s disease in Phase 3 clinical trial titled-KINECT-HD. Furthermore, a research paper was published in May 2021 in the journal Brain that demonstrates that the use of gene editing therapy in the early stages of Disease exhibits the potential to slow down symptom progression. These ongoing studies are anticipated to play a crucial role in defining the market share of this segment in the coming years.
North America is Expected to Hold a Significant Share in the Market and Expected to Maintain its Dominance in the Forecast Period.
The anticipated large share of North America can be attributed to the rising burden of the disease. According to data published by Cleveland Clinic in January 2020, this disease affects about 30,000 Americans. The prevalence of disease in North America was 5.7 per 100,000 people. Furthermore, market players are playing a crucial role in accelerating market growth through the expansion of their product portfolio and pipeline programs. For instance, in June 2021, a United States-based company Galyan Bio announced its plans to commence a clinical trial in collaboration with Bicoll GmbH for its small molecules candidate that aimed at slowing the progression of Huntington’s disease. Furthermore, in January 2022, Ionis Pharmaceuticals, Inc. and Roche announced to design a new Phase 2 trial for evaluation of tominersen in Huntington’s disease (HD). These developments are anticipated to positively impact the market growth in North America.
In addition, the active participation of regulatory bodies in safe and effective approval of products for human use is contributing to the market revenue. In September 2021, the FDA granted fast track designation to Sage Therapeutics Inc.’s SAGE-718, a potential treatment for HD. Furthermore, market players are expanding the application of their approved therapies for the inclusion of HD as an indication. For example, San Diego-based Neurocrine announced to expand the application of Ingrezzia (valbenazine), a drug which is first approved in 2017 by the FDA for treatment of tardive dyskinesia (TD), for treatment of Chorea in Huntington’s disease. The company anticipated filing of supplemental New Drug Application for this indication in the second half of 2022. These developments are playing a major role in driving revenue for North America market.
Huntingtons Disease Treatment Market Competitor Analysis
The Huntington’s disease treatment market is currently fragmented in nature with presence of several large to small and medium sized players. Some of the companies which are currently dominating the market are Pfizer, Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Ionis Pharmaceuticals, Neurocrine Biosciences, Inc., Prilenia Therapeutics, Azevan Pharmaceuticals, and Lundbeck.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and market defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Huntington’s In Developed Countries
4.2.2 Robust Funding for Huntington’s Disease Research
4.3 Market Restraints
4.3.1 High R&D Cost
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Symptomatic Treatment
5.1.2 Disease-modifying Therapies
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Alnylam Pharmaceuticals Inc
6.1.3 Ceregene Inc.
6.1.4 Prana Biotechnology Limited
6.1.5 Teva Pharmaceutical Industries Ltd.
6.1.6 Ionis Pharmaceuticals
6.1.7 Neurocrine Biosciences, Inc.
6.1.8 Prilenia Therapeutics
6.1.9 Azevan Pharmaceuticals
6.1.10 Lundbeck
7 MARKET OPPORTUNITIES AND FUTURE TRENDS